Eli Lilly (LLY) Says Data Shows Benefit of Early Treatment with Solanezumab in Mild Alzheimer's Disease
Tweet Send to a Friend
Eli Lilly and Company (NYSE: LLY) today announced results suggesting the treatment effect of solanezumab was preserved within a pre-specified ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
